FDA Approves Obinutuzumab for Active Lupus Nephritis
The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.
https://t.co/Wr3tG5izCi https://t.co/P8A5PUCIX0
Links:
FDA Approves Obinutuzumab for Active Lupus Nephritis | RheumNow
https://buff.ly/uAm5rY4
26-10-2025


